Cidara Therapeutics, Inc. (CDTX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 12:11PM EDT. Market open.
| Previous close | 12.51 |
| Open | 12.60 |
| Bid | 13.41 x 100 |
| Ask | 13.65 x 100 |
| Day's range | 12.60 - 13.65 |
| 52-week range | 10.00 - 29.60 |
| Volume | |
| Avg. volume | 62,191 |
| Market cap | 61.994M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
Steven Cohen (Trades, Portfolio)'s investment firm, Point72, has recently expanded its portfolio with the addition of Cidara Therapeutics Inc (NASDAQ:CDTX). On December 31, 2023, Point72 acquired 1,250,228 shares of the biotechnology company, reflecting a new position in the firm's diverse investment landscape. The transaction was executed at a trade price of $0.794 per share, marking a strategic move by one of the industry's leading investment entities.
- Zacks
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.
- Simply Wall St.
Cidara Therapeutics (NASDAQ:CDTX) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
© 2024 Yahoo. All rights reserved.